Note: EPS may not be comparable

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.80), $0.15 worse than the analyst estimate of ($0.65).

Financial Outlook

Based on current operating plans, Karyopharm expects that its existing cash, cash equivalents and investments will be sufficient to fund its operations through at least the first quarter of 2019. These plans include the continued clinical development of selinexor in the Company’s lead indications with a focus on filing an NDA with the FDA requesting accelerated approval in MM during 2018, assuming positive data from the STORM study, and preparing the commercial infrastructure for the potential launch of selinexor in the United States. Additional key milestones expected in 2018 include a potential MAA filing to the EMA requesting conditional approval for selinexor in MM, topline data from the SADAL study and completion of enrollment in the Phase 3 BOSTON study.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.